Shares of Qiagen (NYSE:QGEN – Get Free Report) have been given a consensus rating of “Hold” by the ten brokerages that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $48.42.
QGEN has been the subject of a number of research analyst reports. UBS Group lowered their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. StockNews.com upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Baird R W downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird boosted their price objective on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st.
Read Our Latest Report on Qiagen
Institutional Inflows and Outflows
Qiagen Stock Performance
Shares of NYSE:QGEN opened at $42.65 on Wednesday. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30. The stock has a market capitalization of $9.48 billion, a price-to-earnings ratio of 118.76, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company’s 50 day simple moving average is $40.97 and its 200 day simple moving average is $41.81.
Qiagen (NYSE:QGEN – Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The firm had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter last year, the business posted $0.44 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. As a group, research analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Featured Articles
- Five stocks we like better than Qiagen
- What Are Dividend Champions? How to Invest in the Champions
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- What is Short Interest? How to Use It
- Savvy Investors Are Raising a Glass for Heineken Stock
- Best Stocks Under $10.00
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.